CPAY:NYSECorpay, Inc. Analysis
Data as of 2026-05-23 - not real-time
$347.90
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Corpay delivered a "blowout" Q1 FY2026, posting 25.4% year‑over‑year revenue growth to $1.26 billion and a non‑GAAP EPS of $5.80 that topped consensus by 6%, prompting the company to raise its full‑year revenue guidance to $5.29 billion. The stock is trading at $347.9, comfortably above its 20‑day SMA of $326 and the 50‑day SMA of $314, while still below the 200‑day SMA of $309, signaling a bullish momentum that is reinforced by a MACD histogram of +2.38 and an RSI of 63, well under the overbought threshold. Volume has remained stable, and the price is perched near the calculated resistance of $354.97 with a solid support floor at $298.46, suggesting limited upside in the immediate term but room to test the resistance on further earnings momentum.
From a valuation perspective, the discounted cash‑flow model implies a fair value near $1,019, indicating the market is pricing the stock at a roughly 12% discount to intrinsic value. Strong operating margins (41% operating, 25% net) and a free cash flow conversion of over $2 billion underscore the company’s cash‑generating efficiency, yet a debt‑to‑equity ratio above 270% and a price‑to‑book of 6.55 flag balance‑sheet leverage concerns. The absence of a dividend makes the stock a pure growth play, and while beta around 1.2 and a 30‑day volatility of 47% point to heightened price swings, the sector’s technology‑infrastructure backdrop and the company’s U.S.‑centric operations temper broader regulatory and geographic risks.
From a valuation perspective, the discounted cash‑flow model implies a fair value near $1,019, indicating the market is pricing the stock at a roughly 12% discount to intrinsic value. Strong operating margins (41% operating, 25% net) and a free cash flow conversion of over $2 billion underscore the company’s cash‑generating efficiency, yet a debt‑to‑equity ratio above 270% and a price‑to‑book of 6.55 flag balance‑sheet leverage concerns. The absence of a dividend makes the stock a pure growth play, and while beta around 1.2 and a 30‑day volatility of 47% point to heightened price swings, the sector’s technology‑infrastructure backdrop and the company’s U.S.‑centric operations temper broader regulatory and geographic risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish MACD and SMA alignment
- Price near short‑term resistance
- Stable trading volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust 25% revenue growth and raised guidance
- Undervalued relative to DCF fair value
- High operating and net margins
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Recurring payments franchise with strong cash generation
- Strategic positioning in corporate spend management
- Long‑term upside potential despite current leverage
Key Metrics & Analysis
Financial Health
Revenue Growth25.40%
Profit Margin24.60%
P/E Ratio20.8
ROE32.12%
ROA6.19%
Debt/Equity271.34
P/B Ratio6.6
Op. Cash Flow$1.5B
Free Cash Flow$2.1B
Industry P/E39.5
Technical Analysis
TrendBullish
RSI63.1
Support$298.46
Resistance$354.97
MA 20$326.04
MA 50$313.68
MA 200$308.99
MACDBullish
VolumeStable
Fear & Greed Index91.61
Valuation
Fair Value$1,018.81
Target Price$389.79
Upside/Downside12.04%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.24
Volatility46.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.